Editas, Neurocrine Snag Orphan Drug Designations as Congressional Debate Continues Beta Thalassemia, Clinical Data, Congress, FDA, Gene Therapy, Huntington’s disease, Orphan Drug Designation, Pediatric Diseases, R&D, Sickle Cell Disease, Topline Data, World Orphan Drug Alliance (WODA) As the fairness of orphan drug exclusivities is debated in Congress, the U.S. Food and Drug Administration granted Orphan Drug designations to Editas Medicine and Neurocrine Biosciences. Read more May 13, 2022/by BioSpace https://www.pharmalive.com/wp-content/uploads/2022/05/Editas-Neurocrine-Snag-Orphan-Drug-Designations-as-Congressional-Debate-Continues-BioSpace-5-13-22.jpeg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2022-05-13 15:02:592022-05-13 15:03:28Editas, Neurocrine Snag Orphan Drug Designations as Congressional Debate Continues